Table 1.
Baseline and procedural characteristics
| Characteristics | Acute coronary syndromes |
Chronic coronary syndromes |
Pa | ||||||
|---|---|---|---|---|---|---|---|---|---|
| All, N = 673 | Supreme DES n = 441 | DP-EES n = 232 | P | All, N = 955 | Supreme DES, n = 645 | DP-EES, n = 310 | P | ||
| Age, y | 62.6 ± 10.5 | 62.9 ± 10.3 | 62.0 ± 10.8 | .34 | 65.6 ± 9.4 | 65.7 ± 9.4 | 65.4 ± 9.6 | .83 | <.0001 |
| Female sex | 24.2% (163) | 21.3% (94) | 29.7% (69) | .17 | 25.4% (243) | 25.4% (164) | 25.5% (79) | .98 | .57 |
| Smoker (current/previous) | 64.2% (432) | 62.4% (275) | 67.7% (157) | .41 | 58.1% (555) | 60.5% (390) | 53.2% (165) | .03 | <.0001 |
| Diabetes mellitus | 25.4% (171) | 25.4% (112) | 25.4% (59) | .99 | 33.8% (323) | 34.0% (219) | 33.5% (104) | .90 | .0003 |
| Insulin treatment | 33.9% (58) | 35.7% (40) | 30.5% (18) | .37 | 33.4% (108/323) | 32.4% (71/219) | 35.6% (37/104) | .29 | .47 |
| Hypertension | 68.8% (463) | 71.2% (314) | 64.2% (149) | .06 | 75.6% (722) | 76.3% (492) | 74.2% (230) | .48 | .002 |
| Hyperlipidemia | 71.9% (484) | 72.1% (318) | 71.6% (166) | .88 | 80.2% (766) | 80.5% (519) | 79.7% (247) | .77 | <.0001 |
| Previous MI | 15.3% (103) | 16.3% (72) | 13.4% (31) | .31 | 19.6% (187) | 18.1% (117) | 22.6% (70) | .11 | .03 |
| Previous PCI | 22.7% (153) | 23.8% (105) | 20.7% (48) | .36 | 33.2% (317) | 30.9% (199) | 38.1% (118) | .03 | <.0001 |
| Previous CABG | 2.8% (19) | 3.4% (15) | 1.7% (4) | .21 | 6.0% (57) | 5.9% (38) | 6.1% (19) | .88 | .003 |
| Previous stroke | 2.8% (19) | 2.5% (11) | 3.4% (8) | .48 | 4.8% (46) | 5.4% (35) | 3.5% (11) | .20 | .043 |
| Renal insufficiency | 7.9% (53) | 7.9% (35) | 7.8% (18) | .74 | 8.0% (76) | 7.9% (51) | 8.1% (25) | .93 | .95 |
| No. of diseased vessels | |||||||||
| 1 | 68.9% (464) | 70.1% (309) | 66.8% (155) | .39 | 73.2% (699) | 74.3% (479) | 71.0% (220) | .28 | .06 |
| 2 | 24.2% (163) | 21.8% (96) | 28.9% (67) | .04 | 18.6% (178) | 18.1% (117) | 19.7% (61) | .57 | .006 |
| ≥3 | 6.9% (46) | 8.1% (36) | 4.3% (10) | .02 | 8.2% (78) | 7.6% (49) | 9.3% (29) | .43 | .29 |
| Procedural characteristics | |||||||||
| No. of vessels treated per patient | 1.14 ± 0.35 | 1.14 ± 0.36 | 1.13 ± 0.34 | .91 | 1.11 ± 0.31 | 1.10 ± 0.29 | 1.14 ± 0.35 | .05 | .12 |
| Multiple vessels treated | 13.5% (91) | 13.6% (60) | 13.4% (31) | .94 | 11.0% (105) | 9.6% (62) | 13.9% (43) | .05 | .17 |
| No. of target lesions per patient | 1.2 ± 0.5 | 1.2 ± 0.5 | 1.2 ± 0.4 | .43 | 1.2 ± 0.5 | 1.2 ± 0.4 | 1.3 ± 0.5 | .06 | .44 |
| 1 | 79.5% (532/672) | 80.5% (355) | 77.5% (179/231) | .36 | 81.3% (776) | 82.8% (534) | 78.1% (242) | .08 | .37 |
| 2 | 18.6% (125/672) | 17.0% (75) | 21.6% (50/231) | .14 | 15.8% (151) | 15.0% (97) | 17.4% (54) | .35 | .14 |
| 3 | 1.9% (13/672) | 2.5% (11) | 0.9% (2/231) | .24 | 2.9% (28) | 2.2% (14) | 4.5% (14) | .04 | .21 |
| No. of stents per patient | 1.3 ± 0.6 | 1.2 ± 0.6 | 1.3 ± 0.6 | .10 | 1.2 ± 0.6 | 1.2 ± 0.6 | 1.3 ± 0.6 | .09 | .82 |
| Radial access | 85.7% (577) | 86.4% (381) | 84.5% (196) | .50 | 76.5% (731) | 77.4% (499) | 74.8% (232) | .39 | <.0001 |
| Brachial access | 0.3% (2) | 0.2% (1) | 0.4% (1) | 1.0 | 0.6% (6) | 0.6% (4) | 0.6% (2) | 1.0 | .48 |
| Femoral access | 14.0% (94) | 13.4% (59) | 15.1% (35) | .54 | 22.8% (218) | 22.0% (142) | 24.5% (76) | .39 | <.0001 |
| Hemostasis device use | 76.7% (516) | 77.8% (343) | 74.6% (173) | .35 | 71.3% (681) | 72.1% (465) | 69.7% (216) | .44 | .016 |
Values are given as mean ± standard deviation or % (n).
CCS, chronic coronary syndromes; DES, drug-eluting stent; DP-EES, durable polymer everolimus-eluting stent.
a
All patients with acute coronary syndromes (ACS) vs all patients with CCS regardless of stent.